Request title: Treatment of melanoma and breast cancer

Reference Number: F2739 Date of Response: 23/11/2020

Further to your Freedom of Information Act request, please find the Trust’s response, in blue bold text below:

Request and Royal Devon and Exeter NHS Foundation Trust Response

1. How many patients are currently (past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+ ?

108. Please note this will include same patients receiving primary and then any subsequent treatment in the period range)

*≤5 patients recorded as BRAF+

*Five ≤5.

In accordance with section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients is less than or equal to five and could risk the identification of those patients and breach Caldicott principles.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG’s providers and Trusts may allow identification of patients and should not be published.

2. For patients currently (past 3 months) under treatment for melanoma How many patients are Stage IIIa? *Five ≤5. How many patients are Stage III resectable?. All of the patients

How many Stage III patients received a complete resection in the past 3 months? All of the above patients.

3. In the past 3 months, how many melanoma patients were treated with the following: · Bevacizumab – 0 patients · Cobimetinib – 0 patients · Dabrafenib – ≤5 patients · Dabrafenib AND Trametinib – 11 patients · Dacarbazine – 0 patients · Encorafenib AND Binimetinib – 0 patients · Ipilimumab – 0 patients · Ipilimumab AND Nivolumab – ≤5patients · Nivolumab – 35 patients · Pembrolizumab – 15 patients · Trametinib – 0 patients · Vemurafenib – 0 patients · Vemurafenib AND Cobimetinib – 0 patients · Other active systemic anti-cancer therapy – ≤5 patients on other chemo care · Palliative care only · Palliative care only *Five ≤5 Specialist Palliative Care

4. In the past 3 months how many patients were treated with the following for breast cancer? · Abemaciclib + Anastrozole/Exemestane/Letrozole – 0 patients · Abemaciclib + Fulvestrant – 13 patients · Alpelisib + Fulvestrant – 0 patients · Atezolizumab – ≤5 patients · Bevacizumab – 0 patients · Eribulin – ≤5 patients · Everolimus + Exemestane – ≤5 patients · Fulvestrant as a single agent – 0 patients · Gemcitabine + Paclitaxel – 0 patients · Lapatinib – ≤5 patients · Neratinib – ≤5 patients · Olaparib – ≤5 patients · Palbociclib + Anastrozole/Exemestane/Letrozole – 24 patients · Palbociclib + Fulvestrant – ≤5 patients · Pertuzumab + Trastuzumab + Docetaxel – ≤5 patients · Ribociclib + Anastrozole/Exemestane/Letrozole – 11 patients · Ribociclib + Fulvestrant – 8 patients · Talazoparib – 0 patients · Transtuzumab + Paclitaxel – ≤5 patients · Transtuzumab as a single agent – 24 patients (trastuzumab) · Trastuzumab emtansine – 7 patients · Any other active systemic anti-cancer therapy – 123 patients on other chemo care